|
Market Closed -
Bombay S.E.
03:50:21 11/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 4,763.00 INR | -0.25% |
|
+2.76% | +23.98% |
| Market Cap | 1,81200Cr 1.93TCr 1.73TCr 1.6TCr 1.45TCr 2.74TCr 2.82TCr 19TCr 7.62TCr 97TCr 7.25TCr 7.1TCr 3,06800Cr | P/E 2027 * |
73.2x | P/E 2028 * | 53x |
|---|---|---|---|---|---|
| Enterprise Value | 1,93500Cr 2.06TCr 1.85TCr 1.71TCr 1.55TCr 2.93TCr 3.01TCr 20TCr 8.14TCr 1,03700Cr 7.75TCr 7.58TCr 3,27800Cr | EV / Sales 2027 * |
9.69x | EV / Sales 2028 * | 8.49x |
| Free-Float |
41.28% | Yield 2027 * |
0.62% | Yield 2028 * | 0.73% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| TORNTPHARM | Delayed | |
NSE India S.E.
| TORNTPHARM | Delayed |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -0.25% | ||
| 1 week | +2.76% | ||
| Current month | +2.76% | ||
| 1 month | +2.21% | ||
| 3 months | -3.10% | ||
| 6 months | +8.74% | ||
| Current year | +23.98% |
| 1 week | 4,682.2 |  | 4,835.6 |
| 1 month | 4,465.35 | | 4,835.6 |
| Current year | 3,724.1 | | 5,249.95 |
| 1 year | 3,674.6 | | 5,249.95 |
| 3 years | 2,025 | | 5,249.95 |
| 5 years | 1,242.5 | | 5,249.95 |
| 10 years | 571.75 | | 5,249.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 01/08/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 01/09/2018 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 30/07/2014 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 07/03/2019 |
| Director/Board Member | 59 | 29/07/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/11/24 | Buy | Chief Operating Officer | 9,30,144 | 0.2748% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | +2.76% | +24.77% | +131.51% | 1.94TCr | |
| -1.15% | +0.20% | +43.72% | +131.90% | 1,27600Cr | |
| -1.39% | +0.37% | +43.08% | +87.86% | 68TCr | |
| -1.30% | -1.42% | +29.07% | +109.63% | 52TCr | |
| -0.66% | +1.06% | +38.59% | +67.58% | 39TCr | |
| -1.81% | -3.04% | +60.30% | +42.28% | 36TCr | |
| -1.46% | -1.21% | +27.44% | +56.75% | 31TCr | |
| -0.32% | -1.20% | +2.90% | +35.21% | 29TCr | |
| -0.97% | -3.48% | +36.45% | +73.17% | 25TCr | |
| -0.84% | -2.63% | +38.62% | +126.73% | 21TCr | |
| Average | -1.00% | +2.52% | +34.49% | +86.26% | 43TCr | |
| Weighted average by Cap. | -1.14% | +2.52% | +38.15% | +93.37% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20TCr 212.95Cr 190.97Cr 176Cr 159.83Cr 302.5Cr 310.94Cr 2.11TCr 839.6Cr 11TCr 799.16Cr 782.21Cr 34TCr | 22TCr 239.32Cr 214.62Cr 197.79Cr 179.63Cr 339.96Cr 349.45Cr 2.37TCr 943.58Cr 12TCr 898.13Cr 879.08Cr 38TCr |
| Net income | 2.4TCr 26Cr 23Cr 21Cr 19Cr 36Cr 37Cr 252.93Cr 100.77Cr 1.28TCr 96Cr 94Cr 4.06TCr | 3.39TCr 36Cr 32Cr 30Cr 27Cr 51Cr 53Cr 357.74Cr 142.53Cr 1.82TCr 135.67Cr 132.79Cr 5.74TCr |
| Net Debt | 12TCr 131.65Cr 118.07Cr 108.81Cr 99Cr 187.02Cr 192.24Cr 1.3TCr 519.09Cr 6.61TCr 494.09Cr 483.61Cr 21TCr | 9.29TCr 99Cr 89Cr 82Cr 74Cr 140.81Cr 144.74Cr 980.9Cr 390.82Cr 4.98TCr 371.99Cr 364.1Cr 16TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/26/11 | ₹4,763.00 | -0.25% | 7,881 |
| 09/26/09 | ₹4,775.00 | +0.08% | 7,625 |
| 08/26/08 | ₹4,771.00 | +0.63% | 1,529 |
| 06/26/06 | ₹4,741.00 | +0.49% | 16,268 |
| 05/26/05 | ₹4,717.95 | -0.25% | 6,629 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
